DE10214264A1 - HFA-Suspensionsformulierungen eines Anhydrats - Google Patents

HFA-Suspensionsformulierungen eines Anhydrats

Info

Publication number
DE10214264A1
DE10214264A1 DE10214264A DE10214264A DE10214264A1 DE 10214264 A1 DE10214264 A1 DE 10214264A1 DE 10214264 A DE10214264 A DE 10214264A DE 10214264 A DE10214264 A DE 10214264A DE 10214264 A1 DE10214264 A1 DE 10214264A1
Authority
DE
Germany
Prior art keywords
hfa
suspensions
acid
contain
tiotropium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10214264A
Other languages
German (de)
English (en)
Inventor
Christel Schmelzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10214264A priority Critical patent/DE10214264A1/de
Priority to EA200401159A priority patent/EA008610B1/ru
Priority to MEP-2008-473A priority patent/ME00246B/me
Priority to MXPA04009338A priority patent/MXPA04009338A/es
Priority to PL03371295A priority patent/PL371295A1/xx
Priority to JP2003579782A priority patent/JP5147158B2/ja
Priority to UA20041008758A priority patent/UA79776C2/uk
Priority to PCT/EP2003/002899 priority patent/WO2003082244A2/de
Priority to BR0308709-3A priority patent/BR0308709A/pt
Priority to CNA038072475A priority patent/CN1642525A/zh
Priority to AU2003221509A priority patent/AU2003221509B2/en
Priority to EP03717219A priority patent/EP1492498A2/de
Priority to KR1020047015174A priority patent/KR101005717B1/ko
Priority to YU86004A priority patent/RS52481B/en
Priority to NZ536030A priority patent/NZ536030A/en
Priority to IL16369603A priority patent/IL163696A0/xx
Priority to CA2479638A priority patent/CA2479638C/en
Priority to US10/400,127 priority patent/US7244415B2/en
Publication of DE10214264A1 publication Critical patent/DE10214264A1/de
Priority to ZA2004/05637A priority patent/ZA200405637B/en
Priority to NO20044004A priority patent/NO20044004L/no
Priority to HR20040890A priority patent/HRP20040890A2/hr
Priority to EC2004005322A priority patent/ECSP045322A/es
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE10214264A 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats Withdrawn DE10214264A1 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats
MXPA04009338A MXPA04009338A (es) 2002-03-28 2003-03-20 Formulaciones de un anhidrato en suspension con hfa.
BR0308709-3A BR0308709A (pt) 2002-03-28 2003-03-20 Formulações em suspensão de hfa de um anidrato
EP03717219A EP1492498A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats
PL03371295A PL371295A1 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate
JP2003579782A JP5147158B2 (ja) 2002-03-28 2003-03-20 無水物のｈｆａ懸濁製剤
UA20041008758A UA79776C2 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of crystalline tiotropium bromide anhydrate and use thereof
PCT/EP2003/002899 WO2003082244A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats
MEP-2008-473A ME00246B (me) 2002-03-28 2003-03-20 Formulacije hfa-suspenzija koje sadrže anhidrat
CNA038072475A CN1642525A (zh) 2002-03-28 2003-03-20 无水化合物的hfa混悬剂
YU86004A RS52481B (en) 2002-03-28 2003-03-20 FORMULATION OF HFA-SUSPENSION CONTAINING ANHYDRATE
EA200401159A EA008610B1 (ru) 2002-03-28 2003-03-20 Суспензионные препараты на основе кристаллического ангидрата тиотропийбромида
KR1020047015174A KR101005717B1 (ko) 2002-03-28 2003-03-20 무수물의 ｈｆａ-현탁 제형
AU2003221509A AU2003221509B2 (en) 2002-03-28 2003-03-20 HFA-suspension formulation of an anhydrate
NZ536030A NZ536030A (en) 2002-03-28 2003-03-20 HFA-suspension formulation of crystalline tiotropium bromide anhydrate
IL16369603A IL163696A0 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate
CA2479638A CA2479638C (en) 2002-03-28 2003-03-20 Hfa-suspension formulations of crystalline tiotropium bromide anhydrate
US10/400,127 US7244415B2 (en) 2002-03-28 2003-03-26 HFA suspension formulations of an anhydrate
ZA2004/05637A ZA200405637B (en) 2002-03-28 2004-07-15 Hfa-suspension formulation of an anhydrate
NO20044004A NO20044004L (no) 2002-03-28 2004-09-23 HFA-Suspensjonsformulering av et anhydrat
HR20040890A HRP20040890A2 (en) 2002-03-28 2004-09-27 Hfa-suspension formulation of an anhydrate
EC2004005322A ECSP045322A (es) 2002-03-28 2004-09-28 Formulaciones de un anhidrato en suspensión con hfa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats

Publications (1)

Publication Number Publication Date
DE10214264A1 true DE10214264A1 (de) 2003-10-16

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10214264A Withdrawn DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats

Country Status (21)

Country Link
EP (1) EP1492498A2 (ru)
JP (1) JP5147158B2 (ru)
KR (1) KR101005717B1 (ru)
CN (1) CN1642525A (ru)
AU (1) AU2003221509B2 (ru)
BR (1) BR0308709A (ru)
CA (1) CA2479638C (ru)
DE (1) DE10214264A1 (ru)
EA (1) EA008610B1 (ru)
EC (1) ECSP045322A (ru)
HR (1) HRP20040890A2 (ru)
IL (1) IL163696A0 (ru)
ME (1) ME00246B (ru)
MX (1) MXPA04009338A (ru)
NO (1) NO20044004L (ru)
NZ (1) NZ536030A (ru)
PL (1) PL371295A1 (ru)
RS (1) RS52481B (ru)
UA (1) UA79776C2 (ru)
WO (1) WO2003082244A2 (ru)
ZA (1) ZA200405637B (ru)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138862A3 (en) * 2009-05-29 2011-04-14 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2018282272B2 (en) * 2009-05-29 2020-05-14 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007144531A (ru) * 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Новые кристаллические формы тиотропийбромида
AU2006243238B2 (en) * 2005-05-02 2012-05-24 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
JP6781831B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE50115277D1 (de) * 2000-10-31 2010-02-04 Boehringer Ingelheim Pharma Arzneimittelkompositionen aus tiotropiumsalzen und
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138862A3 (en) * 2009-05-29 2011-04-14 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
WO2010138884A3 (en) * 2009-05-29 2011-04-21 Pearl Therapeutics, Inc. Respiratory delivery of active agents
WO2010138868A3 (en) * 2009-05-29 2011-04-28 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
CN102596176A (zh) * 2009-05-29 2012-07-18 珍珠治疗公司 经呼吸递送活性剂的组合物及相关方法和系统
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US8703806B2 (en) 2009-05-29 2014-04-22 Pearl Therapeutics, Inc. Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2010253770B2 (en) * 2009-05-29 2014-12-11 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
AU2010253776B2 (en) * 2009-05-29 2015-01-22 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
AU2018282272B2 (en) * 2009-05-29 2020-05-14 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
RU2751771C2 (ru) * 2009-05-29 2021-07-16 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Also Published As

Publication number Publication date
BR0308709A (pt) 2005-01-04
JP2005527550A (ja) 2005-09-15
UA79776C2 (en) 2007-07-25
JP5147158B2 (ja) 2013-02-20
HRP20040890A2 (en) 2005-06-30
RS52481B (en) 2013-02-28
MXPA04009338A (es) 2005-01-25
NZ536030A (en) 2006-07-28
AU2003221509A1 (en) 2003-10-13
EP1492498A2 (de) 2005-01-05
CN1642525A (zh) 2005-07-20
AU2003221509B2 (en) 2008-01-24
ZA200405637B (en) 2005-07-27
KR101005717B1 (ko) 2011-01-05
WO2003082244A2 (de) 2003-10-09
IL163696A0 (en) 2005-12-18
CA2479638C (en) 2011-01-04
PL371295A1 (en) 2005-06-13
MEP47308A (en) 2011-02-10
ECSP045322A (es) 2005-01-28
EA200401159A1 (ru) 2005-04-28
ME00246B (me) 2011-05-10
EA008610B1 (ru) 2007-06-29
CA2479638A1 (en) 2003-10-09
WO2003082244A3 (de) 2004-02-05
KR20040098022A (ko) 2004-11-18
YU86004A (sh) 2006-08-17
NO20044004L (no) 2004-10-05

Similar Documents

Publication Publication Date Title
EP1809243B1 (de) Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel
EP1326862B1 (de) Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
EP0843676B1 (de) Arzneimittelvorbereitungen enthaltend ein enantiomer von ipratropiumbromid mit verlängerter wirkungsdauer
EP1514546B1 (de) Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
EP1682542B1 (de) Neues kristallines anhydrat mit anticholinerger wirksamkeit
WO1993018746A1 (de) Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
US20080044361A1 (en) HFA Suspension Formulations Containing an Anticholinergic
EP1492513B1 (de) Hfa-suspensionsformulierungen enthaltend ein anticholinergikum
EP2083007A1 (de) Tiotropiumsalze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittelformulierungen
DE10214264A1 (de) HFA-Suspensionsformulierungen eines Anhydrats
EP1682541B1 (de) Verfahren zur herstellung von tiotropiumsalzen
US7244415B2 (en) HFA suspension formulations of an anhydrate
DE102004032322A1 (de) Aerosolsuspensionsformulierungen mit TG 227 ea als Teibmittel
DE10209243A1 (de) Neue Arzneimittelkombination zur Inhalation
DE10145438A1 (de) Neue Arzneimittel zur Inhalation

Legal Events

Date Code Title Description
8141 Disposal/no request for examination